Moritz Zimmermann

Moritz Zimmermann

Auto-generated profile, based on publicly available information

Moritz Zimmermann

Technische Universität Braunschweig

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MTMarie Thiemann
Marie Thiemann
MZMoritz Zimmermann
Moritz Zimmermann
CDChristina Diederich
Christina Diederich
HZHuilin Zhan
Huilin Zhan
MLMikhail Lebedev
Mikhail Lebedev
WBWulf Blankenfeldt
Wulf Blankenfeldt
The human pathogen Pseudomonas aeruginosa is particularly notorious for its multiple resistance mechanisms. A new concept for anti-infectives is the "pathoblocker" approach, which targets virulence factors to disarm rather than kill pathogens and thus attenuates the development of resistance. Based on the estrogen receptor modulator raloxifene, which had previously been identified as a potential biosynthesis inhibitor of the virulence factor pyocyanin via in silico screening, analogues have been developed as pathoblockers against P. aeruginosa. These compounds reduce the production of pyocyanin by binding to the phenazine biosynthesis enzyme PhzB. Structure-activity relationships (SAR) were explored using nano differential scanning fluorimetry, isothermal titration calorimetry, and 12 X-ray cocrystal structures. Compared to raloxifene, congener 20c shows a 60-fold lower affinity for the human estrogen receptor with a 15-fold increase in pyocyanin inhibitory activity. The comprehensive structural information gathered in this study paves the way for the development of improved pathoblockers with increased potency and selectivity.

29 October 2024 in ChemMedChem
Verified
Journal Article
Open access
JBJanosch Baumgarten
Janosch Baumgarten
PSPhilipp Schneider
Philipp Schneider
MTMarie Thiemann
Marie Thiemann
MZMoritz Zimmermann
Moritz Zimmermann
CDChristina Diederich
Christina Diederich
CKConrad Kunick
Conrad Kunick
The phenazine pyocyanin is an important virulence factor of the pathogen Pseudomonas aeruginosa, which is on the WHO list of antibiotic resistant “priority pathogens”. In this study the isomerase PhzF, a key bacterial enzyme of the pyocyanin biosynthetic pathway, was investigated as a pathoblocker target. The aim of the pathoblocker strategy is to reduce the virulence of the pathogen without killing it, thus preventing the rapid development of resistance. Based on crystal structures of PhzF, derivatives of the inhibitor 3–hydroxyanthranilic acid were designed. Co‐crystal structures of the synthesized derivatives with PhzF revealed spacial limitations of the binding pocket of PhzF in the closed conformation. In contrast, ligands aligned to the open conformation of PhzF provided more room for structural modifications. The intrinsic fluorescence of small 3–hydroxyanthranilic acid derivatives enabled direct affinity determinations using FRET assays. The analysis of structure‐activity relationships showed that the carboxylic acid moiety is essential for binding to the target enzyme. The results of this study provide fundamental structural insights that will be useful for the design of PhzF‐inhibitors.

10 September 2026 in ACS Bio & Med Chem Au
Verified
Journal Article
Open access
MHMaria Handke
Maria Handke
JBJanosch Baumgarten
Janosch Baumgarten
MTMarie Thiemann
Marie Thiemann
MZMoritz Zimmermann
Moritz Zimmermann
MEMartin Empting
Martin Empting
MSMatthias Schiedel
Matthias Schiedel
Phenazines are redox-active secondary metabolites produced by a variety of bacteria, including Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen associated with severe, often chronic infections and particularly notorious for its multiple resistance mechanisms. A major contributor to P. aeruginosa virulence and resistance is the production of phenazine-derived metabolites such as pyocyanin, which play central roles in biofilm formation, redox homeostasis, and host tissue damage. Consequently, inhibition of phenazine biosynthesis may be an attractive pathoblocker strategy aimed at attenuating bacterial virulence without exerting bactericidal pressure, thus reducing the development of drug resistance. Over the past years, considerable progress has been made in the identification and characterization of small-molecule inhibitors targeting this pathway. These advances have been driven by interdisciplinary efforts, with medicinal chemistry, chemical biology, and structural biology providing key insights into target tractability, ligand binding modes, and structure–activity relationships. In this review, we summarize recent developments in phenazine biosynthesis inhibition, highlighting representative inhibitors and discussing biological and structural data for enzymes across the pathway.